Parabilis Medicines, Inc. Common Stock
Follow $PBLS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PBLS by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PBLS moving today?
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PBLS overview
Related filings and maps
Congress activity in PBLS
No receipt-qualified Congressional disclosure is present for PBLS in the cached public ledger.
PBLS contract awards, year to date.
Public federal awards linked to this ticker.
PBLS lobbying filings, year to date.
Registered lobbying filings matched to Parabilis Medicines, Inc. Common Stock.